Asthma is a heterogeneous chronic syndrome which represents a relevant socioeconomic burden in both adults and children. Global asthma prevalence has been reported to be of approximately 300 million people, with an estimate of increasing figures up to 400 million by 20251 . Among the identified distinct phenotypes and endotypes2 , allergic asthma represents one of the most well-characterized and relevant nosologic entity, with atopy playing a key role in the disease risk, onset and progression. This article is protected by copyright. All rights reserved.

中文翻译：

---

哮喘过敏原免疫疗法：展望“回到未来”

哮喘是一种异质性慢性综合征，代表成人和儿童的相关社会经济负担。据报道，全球哮喘患病人数约为 3 亿人，估计到 20251 年这一数字将增加至 4 亿人。在已确定的不同表型和内型 2 中，过敏性哮喘代表了最充分表征和相关的疾病学实体之一，特应性在疾病风险、发病和进展中起着关键作用。本文受版权保护。版权所有。